ReviewRegenerative potential of allopregnanolone
Section snippets
Unmet therapeutic need: prevention and delay of Alzheimer's disease
Currently more than 5 million Americans suffer from Alzheimer's which costs approximately $100 billion dollars per year (Fillit and Hill, 2005, Hebert et al., 2001, Refolo and Fillit, 2006). Approximately, 360,000 new cases of AD occur each year in the United States. Conservative projections predict that the prevalence of AD will nearly quadruple within just 43 years, at which point 14 million older Americans are expected to have AD (Mount and Downton, 2006). If no effective preventive
Microenvironment supporting neurogenesis during aging and AD progression
In the developing brain, most stem cells and microenvironments are spatially shifting and are temporally transient as the cellular and molecular programs of neurogenesis and morphogenesis are “assembled and disassembled” (Alvarez-Buylla and Lim, 2004). In contrast to the undulating milieu of stem cell zones in the embryonic nervous system, the adult brain restricts neural stem cells and their proliferation to select microenvironments. These specialized domains, the subventricular zone (SVZ) of
Challenges of regenerative therapeutics for Alzheimer's disease
While the therapeutic potential of neural stem cells is great, so too are the challenges. AD is a diffuse degenerative disease with pathology and neuronal death occurring in multiple brain regions. Four regions within the AD brain show evidence of aberrant entry into the cell cycle predictive of neuronal loss: the hippocampus, subiculum, locus caeruleus and dorsal raphe nucleus (Busser et al., 1998). In addition to these sites is the late stage loss of cholinergic neurons likely due to the loss
The role of progesterone and allopregnanolone on growth factor expression
Gonadal hormones are potent regulators of growth factor expression. Best known is estrogen and progesterone regulation of BDNF (Berchtold et al., 2001, Gibbs, 1999, Jezierski and Sohrabji, 2003, Scharfman and Maclusky, 2005, Toran-Allerand, 1996). As expected, growth factors are increased during pregnancy. In particular EGF, IGF and TGFβ1 are all upregulated at the same time progesterone and hence APα are increased (Lennard et al., 1995a, Lennard et al., 1995b, Lennard et al., 1998, Stewart et
PK/PD/Tox relevant to developing allopregnanolone as a small molecule, blood–brain barrier permeable neurogenic agent
Unlike large molecular weight growth factors, such as FGF and neurotrophins, which do not readily pass the blood–brain barrier, APα with a steroidal chemical structure, 3α-hydroxy-5α-pregnan-20-one, low molecular weight of 318.49 and hydrophobic properties (LogP value = 4.2) easily penetrates the blood–brain barrier. APα induces several CNS effects including antianxiolytic, antiseizure and our data indicate neurogenesis. Our GC/MS data demonstrate that APα is significantly and linearly increased
APα as a regenerative factor to promote functional neurogenesis and diminish Alzheimer's pathology
Recently, we demonstrated that APα promoted in vitro proliferation of human and rat neural progenitors and mouse hippocampal neurogenesis in vivo in a dose-dependent and steroid-specific manner (Wang et al., 2005). The proliferative effect of APα we observed in rat hippocampal neural progenitor cells and human cerebral cortical neural progenitor cells in vitro (Wang et al., 2005) was also observed in rodent cerebellar granule cells which also undergo proliferation during development (Keller et
The effects of APα on learning and memory
It has been well known that learning and memory is influenced by fluctuations in steroid hormones (Frye et al., 2007, Mayo et al., 1993, Mayo et al., 2005, Walf et al., 2006). Interestingly, the age and AD disease related decline of APα is also paralleled by the learning and memory loss. Therefore, it was of particular interest to investigate the effects of APα on learning and memory.
In the past decades, several groups have investigated the effects of APα on behavior, particularly on learning
Therapeutic potential of APα as a regenerative factor
The small molecular weight, steroidal chemical structure and hydrophobic properties of APα make it an ideal molecule to penetrate the blood–brain barrier. Our discovery that APα is a proliferative agent for neural progenitor cells in vitro and in vivo suggests that APα could act to promote proliferation in the AD brain. Further, the very preliminary finding that APα could delay or diminish AD pathology burden suggests that APα could be a multifaceted regenerative therapeutic to both promote the
Acknowledgments
This work was supported by a grant from the Institute for the Study of Aging/Alzheimer's Drug Discovery Foundation to and the Kenneth T. and Eileen Norris Foundation to RDB.
References (134)
- et al.
For the long run: maintaining germinal niches in the adult brain
Neuron
(2004) - et al.
Neurosteroids: a new brain function?
J. Steroid. Biochem. Mol. Biol.
(1990) - et al.
Neurosteroids: beginning of the story
Int. Rev. Neurobiol.
(2001) - et al.
The amyloid precursor protein-binding protein APP-BP1 drives the cell cycle through the S-M checkpoint and causes apoptosis in neurons
J. Biol. Chem.
(2000) - et al.
GABA mediated excitation in immature rat CA3 hippocampal neurons
Int. J. Dev. Neurosci.
(1990) - et al.
Tapered progesterone withdrawal promotes long-term recovery following brain trauma
Exp. Neurol.
(2006) - et al.
Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex
Neuroscience
(2004) - et al.
5-Alpha-dihydroprogesterone formation in human placenta from 5alpha-pregnan-3beta/alpha-ol-20-ones and 5-pregnan-3beta-yl-20-one sulfate
J. Steroid Biochem. Mol. Biol.
(1997) - et al.
Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces
Neuron
(2001) - et al.
Economics of dementia and pharmacoeconomics of dementia therapy
Am. J. Geriatr. Pharmacother.
(2005)